Advertisement
Collaboration › Details
Twist Bioscience–JPMorgan Chase: investor conference, 202401 supply service Twist Bioscience presents at JP Morgan Healthcare Conference 2024
Period | 2024-01-08 | |
Region | San Francisco, CA | |
Country | United States (USA) | |
Partner, 1st | Twist Bioscience Corporation (Nasdaq: TWST) | |
Group | Twist Bioscience (Group) | |
Partner, 2nd | J.P. Morgan Securities LLC | |
Group | JPMorgan Chase (Group) | |
Product | J.P. Morgan 42nd Annual Healthcare Conference 2024 San Francisco | |
Product 2 | synthetic biotechnology | |
Person | LeProust, Emily M. (Twist Bioscience 2013– CEO + Co-Founder before Agilent Director Genomics Application Development) | |
Person 2 | Bitting, Angela (Twist Bioscience 202002 Media Contact) | |
Twist Bioscience Corporation. (12/18/23). "Press Release: Twist Bioscience to Present at 42nd Annual J.P. Morgan Healthcare Conference". South San Francisco, CA.
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 5:15 p.m. Pacific Time in San Francisco, CA.
The presentation will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live events.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
[email protected]
For Media:
Amanda Houlihan
Communications Generalist
774-265-5334
[email protected]
Record changed: 2024-12-20 |
Advertisement
More documents for Twist Bioscience (Group)
- [1] Twist Bioscience Corporation. (12/18/23). "Press Release: Twist Bioscience to Present at 42nd Annual J.P. Morgan Healthcare Conference". South San Francisco, CA....
- [2] Twist Bioscience Corporation. (10/5/23). "Press Release: Twist Bioscience Enters into Antibody Discovery and Licensing Option Agreement with Bayer of up to $188 Million". Hamburg & Singapore....
- [3] Twist Bioscience Corporation. (9/27/23). "Press Release: Twist Bioscience and IMIDomics Collaborate to Discover Antibodies for Applications in Immune-Mediated Inflammatory Diseases". South San Francisco, CA & Rafael, CA & Barcelona....
- [4] Twist Bioscience Corporation. (2/8/22). "Press Release: C2i Genomics Partners with Twist Bioscience to Launch Reference Materials for Whole-Genome Cancer Detection". New York, NY & South San Francisco, CA....
- [5] Twist Bioscience Corporation. (9/9/21). "Press Release: Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration". South San Francisco, CA & Ingelheim....
- [6] Twist Bioscience Corporation. (4/28/21). "Press Release: Twist Bioscience and Vivlion Partner to Generate gRNA Libraries for CRISPR Applications". South San Francisco, CA & Frankfurt am Main....
- [7] Twist Bioscience Corporation. (4/14/21). "Press Release: Pure Biologics Selects Twist Bioscience to Expand Phage Display Technology Capabilities". South San Francisco, CA....
- [8] Twist Bioscience Corporation. (10/13/20). "Press Release: Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies". South San Francisco, CA, Amsterdam & New York, NY....
- [9] Twist Bioscience Corporation. (2/26/20). "Press Release: Twist Bioscience and Sophia Genetics Collaborate to Offer Optimized Genomic Solutions". South San Francisco, CA....
- [10] Twist Bioscience Corporation. (7/25/19). "Press Release: Twist Bioscience Enhances DNA Storage Capabilities Through Agreement With Imagene SA". San Francisco, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top